| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 10/19/2006 | US20060233814 Elimination of heterogeneous or mixed cell population in tumors |
| 10/19/2006 | US20060233811 Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents |
| 10/19/2006 | US20060233810 Methods and compositions for treating or preventing cancer |
| 10/19/2006 | US20060233809 Method for treating prostate conditions |
| 10/19/2006 | US20060233807 Novel therapies and methods of screening for therapeutic compounds |
| 10/19/2006 | US20060233806 Removal promoters and inhibitor for apoptosis cells in vivo |
| 10/19/2006 | US20060233805 Antigen uptake receptor for candida albicans on dendritic cells |
| 10/19/2006 | US20060233783 Topical composition in the form of a gel for treating skin burns |
| 10/19/2006 | US20060233782 Polypeptide; a deletion mutant of chondroitinase ABC Type I truncated by a deletion; retains its proteoglycan degrading activity; neurological functional recovery after central nervous system injury or disease |
| 10/19/2006 | US20060233778 Stability for injection solutions |
| 10/19/2006 | US20060233761 Alkyl-glycoside enhanced vaccination |
| 10/19/2006 | US20060233759 Adenoviral vectors having a protein IX deletion |
| 10/19/2006 | US20060233754 A kit containing a compound promoting delivery of exogenous genes to cells, e.g., 1-(5-chloro-2-hydroxyphenyl)-3-(3-pyridinyl)-1,3-propanedione; 1-Tetradecylarsonic acid; N1-(2-fluoro-9-acridinyl)-N3N3-dimethyl-1,3-propanediamine; and N4(bis(2-chloroethy)amino)benzylidene)1,3-thiazol-2-amine |
| 10/19/2006 | US20060233746 N-terminally chemically modified protein compositions and methods |
| 10/19/2006 | US20060233743 Compositions and methods of therapy |
| 10/19/2006 | US20060233741 Alkylated and polymeric macromolecular antioxidants and methods of making and using the same |
| 10/19/2006 | US20060233739 Treatment of mucocutaneous disorders through reversing chronic imflammation and barrier disruption |
| 10/19/2006 | US20060233738 Composition for promoting production of type 1 collagen and/or elastin |
| 10/19/2006 | US20060233735 Psoriasis; applying daily to hair an aqueous mixture of clobetasol propionate, an anionic surfactant, an amphoteric surfactant, and ethanol; leaving it for 2.5 to 15 minutes, and rinsing with water. |
| 10/19/2006 | US20060233729 Long-acting, chemical-resistant skin emollients, moisturizers, and strengtheners |
| 10/19/2006 | US20060233724 Medicinal composition for peridontal pocket administration containing bisphosphonic acid derivative or its salt as the active ingredient |
| 10/19/2006 | US20060233719 Delivery of antidepressants through an inhalation route |
| 10/19/2006 | US20060233718 heating drugs used for the treatment of anxiety or insomnia, coated on solid supports to form vapors and condensing the vapor to form aerosols comprising microstructure particles of the drugs |
| 10/19/2006 | US20060233717 Dosage form serotonin agonists comprising aerosols formed by heating layers of the drugs on solid supports, to form vapors, then condensing to form condensates which can be administered by breathing; prophylaxis of headaches, migraine |
| 10/19/2006 | US20060233716 Pharmaceutical formulations |
| 10/19/2006 | US20060233707 Process for producing an injectable medicament preparation |
| 10/19/2006 | US20060231452 Titration/compliance pack |
| 10/19/2006 | US20060230983 Treating the the aqueous extract containing a red colorant with a cation exchange resin to associate the colorant with the resin;and eluting the colorant from the resin with an eluting solution containing an alcohol and an acid to yield a red-colored eluate |
| 10/19/2006 | DE202004021099U1 Medical product useful to e.g. treat asthma, comprises a dry powder medicament dose (comprising fine particle dose of tiotropium and at least one dry excipient) loaded into a container for use in a dry powder inhaler |
| 10/19/2006 | DE112004001502T5 Neurobeschützende und Anti-Proliferationsverbindungen Neurobeschützende and anti-proliferative compounds |
| 10/19/2006 | DE112004000712T5 Verfahren zur Herstellung von Amlodipinmesilat-Monohydrat A process for preparing amlodipine mesylate monohydrate |
| 10/19/2006 | DE102005061720B3 Preparing optically active omeprazole enantiomers, useful to treat stomach diseases, comprises oxidizing prochiral sulfide compound with oxidizing agent in presence of titanium complex catalyst and reacting the catalyst with chiral diols |
| 10/19/2006 | DE102005018642A1 Use of ester compounds and/or compounds that are converted to ester compounds in organisms, in preparation of medicament for inhibition of cell proliferation by inhibiting reaction of glyoxalase I and/or II |
| 10/19/2006 | DE102005018641A1 Use of ester compounds and/or compounds that are converted to ester compounds in the organism, in the preparation of a medicament for the inhibition of cell proliferation by inhibiting the reaction of glyoxalase I and/or II |
| 10/19/2006 | DE102005018024A1 New benzazepine stereoisomeric compounds useful as glucocorticoid receptor inhibitors to treat e.g. inflammatory diseases, atopic dermatitis, tumors and eye diseases |
| 10/19/2006 | DE102005017605A1 Substiuierte 2-Aminoalkylthio-benzimidazole, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel Substiuierte 2-aminoalkylthio-benzimidazoles, process for their preparation and their use as medicaments |
| 10/19/2006 | DE102005017316A1 Tetrahydronaphthalinderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Entzündungshemmer Tetrahydronaphthalene derivatives, processes for their preparation and their use as anti-inflammatories |
| 10/19/2006 | DE102005017301A1 Substituierte Chromanderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Entzündungshemmer Substituted chroman derivatives, processes for their preparation and their use as anti-inflammatories |
| 10/19/2006 | DE102005017279A1 Composition (A) with at least two ambient temperatures, useful for glass tampon, comprises a carrier component, and a gas component with specific boiling points |
| 10/19/2006 | DE102005017259A1 Purinderivate Purine derivatives |
| 10/19/2006 | DE102005016634A1 Neuartige Aza-Hetercyclen als Kinase-Inhibitoren Novel aza-heterocycles as kinase inhibitors |
| 10/19/2006 | DE102005016460A1 Spriocyclische Cyclohexanderivate zur Behandlung von Substanzabhängigkeit Spriocyclische cyclohexane derivatives for the treatment of substance dependence |
| 10/19/2006 | CA2823646A1 Dietary supplement, and methods of use |
| 10/19/2006 | CA2778381A1 Dietary supplement, and methods of use |
| 10/19/2006 | CA2606908A1 Use of a metal ion chelating agent for the treatment of animal and human parasites |
| 10/19/2006 | CA2605384A1 (3,4-dihydro-quinazolin-2-yl)-indan-1-yl-amines |
| 10/19/2006 | CA2605377A1 Ghrelin binding nucleic acids |
| 10/19/2006 | CA2605245A1 Glucopyranosyl-substituted (heteroaryloxy-benzyl)-benzene derivatives as sglt inhibitors |
| 10/19/2006 | CA2605224A1 Combination for the therapy of benign prostatic hyperplasia |
| 10/19/2006 | CA2605153A1 Injectable depot formulations and methods for providing sustained release of nanoparticle compositions |
| 10/19/2006 | CA2604952A1 Dietary supplement formulations for improved delivery of coenzyme q10 and methods of administration |
| 10/19/2006 | CA2604887A1 Improved methods of and compositions for the prevention of anxiety, substance abuse, and dependence |
| 10/19/2006 | CA2604862A1 A process for the preparation of an oxaliplatin preparation |
| 10/19/2006 | CA2604836A1 Pyrimidine derivatives and their use in the treatment of cancer |
| 10/19/2006 | CA2604832A1 Medical devices and methods for producing the same |
| 10/19/2006 | CA2604822A1 Novel process for producing ramosetron or its salt |
| 10/19/2006 | CA2604799A1 Use of a sulfonamide compound for improving the pharmacokinetics of a drug |
| 10/19/2006 | CA2604797A1 New tricyclic angiotensin ii agonists |
| 10/19/2006 | CA2604773A1 Npy antagonists, preparation and use |
| 10/19/2006 | CA2604758A1 Beta-2 adrenoceptor agonists for treating connective tissue diseases of the skin |
| 10/19/2006 | CA2604735A1 Nanoparticulate quinazoline derivative formulations |
| 10/19/2006 | CA2604720A1 Polymorphs of 3-o-(3',3'-dimethylsuccinyl)betulinic acid di-n-methyl-d-glucamine |
| 10/19/2006 | CA2604686A1 (1, 10b-dihydro-2-(aminoalkyl- phenyl)-5h-pyraz0l0 [1,5-c] [1,3] benz0xazin-5-yl) phenyl methanone derivatives as hiv viral repliation inhibitors |
| 10/19/2006 | CA2604640A1 Methods for treating diseases through interruption of protein maturation, compounds that inhibit the function of molecular chaperones such as protein disulfide isomerases or interfere with glycosylation, pharmaceutical compositions comprising them, and screening methods for identifying therapeutic agents |
| 10/19/2006 | CA2604629A1 Methods for treating mild cognitive impairment |
| 10/19/2006 | CA2604625A1 A method of treating cancer using dichloroacetate |
| 10/19/2006 | CA2604536A1 Conjugate comprising p21 protein for the treatment of cancer |
| 10/19/2006 | CA2604516A1 Benzimidazole derivatives and their use for modulating the gabaa receptor complex |
| 10/19/2006 | CA2604446A1 Methods and compositions for the treatment of anxiety disorders |
| 10/19/2006 | CA2604400A1 Method of treating or preventing bone deterioration or osteoporosis |
| 10/19/2006 | CA2604397A1 Process for preparing bicyclic compounds |
| 10/19/2006 | CA2604392A1 Quaternary ammonium halides for treatment of infectious conditions |
| 10/19/2006 | CA2604388A1 Preparation of [2-methyl-5-phenyl-3-(piperazin-1-ylmethyl)] pyrrole derivatives |
| 10/19/2006 | CA2604356A1 Aminoalkyl-amidomethyl-substituted 2-(4-sulphonylamino)-3-hydroxy-3,4-dihydro-2h-chromen-6-yl derivatives and their use as potassium channel blockers |
| 10/19/2006 | CA2604353A1 Sulfoximine-pyrimidine macrocycles and the salts thereof , a process for making them, and their pharmaceutical use against cancer |
| 10/19/2006 | CA2604327A1 Pharmaceutical aerosol composition |
| 10/19/2006 | CA2604294A1 Purine derivatives as inhibitors of receptor tyrosine kinase activity |
| 10/19/2006 | CA2604291A1 Compounds which inhibit beta-secretase activity and methods of use thereof |
| 10/19/2006 | CA2604206A1 2-thioethenyl substituted carbapenem derivatives |
| 10/19/2006 | CA2604193A1 A process for the purification of 10-deacetylbaccatine iii from 10-deacetyl-2- debenzoyl-2-pentenoylbaccatine iii |
| 10/19/2006 | CA2604135A1 Pop2 nfkb-inhibiting polypeptides, nucleic acids and methods of use |
| 10/19/2006 | CA2604115A1 Spiro-oxindole compounds and their uses as therapeutic agents |
| 10/19/2006 | CA2604077A1 Method of treating or preventing type-2 diabetes |
| 10/19/2006 | CA2604042A1 Hydroxybenzamide derivatives and their use as inhibitors of hsp90 |
| 10/19/2006 | CA2604038A1 New tricyclic angiotensin ii agonists |
| 10/19/2006 | CA2604028A1 Novel use of zinc gluconate for treating hydradenitis suppurativa |
| 10/19/2006 | CA2604010A1 Spiroheterocyclic compounds and their uses as therapeutic agents |
| 10/19/2006 | CA2603976A1 Methods for treating infectious disease exacerbated asthma |
| 10/19/2006 | CA2603959A1 Therapeutic agent for dyskinesia |
| 10/19/2006 | CA2603941A1 Phenylacetamides suitable as protein kinase inhibitors |
| 10/19/2006 | CA2603935A1 Uses of 2-phenyl-substituted imidazotriazinone derivatives for treating pulmonary hypertension |
| 10/19/2006 | CA2603842A1 Rnai therapeutic for respiratory virus infection |
| 10/19/2006 | CA2603783A1 Pharmaceutical compositions having improved dissolution profiles for poorly soluble drugs |
| 10/19/2006 | CA2603763A1 5-methyl-1-(substituted phenyl)-2-(1h)-pyridone in the manufacture of medicaments for treating fibrosis in organ or tissues |
| 10/19/2006 | CA2603701A1 1,4-substituted piperazine derivative |
| 10/19/2006 | CA2603637A1 Dna-pk inhibitors |
| 10/19/2006 | CA2603634A1 Novel isoindole derivatives, compositions containing same, preparation thereof and pharmaceutical uses thereof in particular as inhibitors of chaperone protein hsp90 activities |
| 10/19/2006 | CA2603533A1 Methods for treating anxiety related disorders |
| 10/19/2006 | CA2603519A1 Methods for the treatment of substance abuse and dependence |
| 10/19/2006 | CA2603457A1 Pyrazolo[1,5-a]pyridine derivatives or pharmaceutically acceptable salts thereof |